157 related articles for article (PubMed ID: 32776923)
1. Efficacy of histamine H1 receptor antagonists azelastine and fexofenadine against cutaneous Leishmania major infection.
Peniche AG; Osorio EY; Melby PC; Travi BL
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008482. PubMed ID: 32776923
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
Nahrevanian H; Farahmand M; Aghighi Z; Assmar M; Amirkhani A
Exp Parasitol; 2007 Jul; 116(3):233-40. PubMed ID: 17335813
[TBL] [Abstract][Full Text] [Related]
3. Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.
Peniche AG; Osorio Y; Renslo AR; Frantz DE; Melby PC; Travi BL
Antimicrob Agents Chemother; 2014; 58(1):78-87. PubMed ID: 24126577
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of anti-leishmanial activity by induction of nitric oxide and inhibition of prostaglandin in Balb/c mice infected with Leishmania major.
Nahrevanian H; Hajihosseini R; Arjmand M; Farahmand M; Ghasemi F
Southeast Asian J Trop Med Public Health; 2009 Nov; 40(6):1188-98. PubMed ID: 20578452
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine.
LaForce CF; Corren J; Wheeler WJ; Berger WE;
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):154-9. PubMed ID: 15328675
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare.
Meltzer EO; Gillman SA
Allergy Asthma Proc; 2007; 28(1):67-73. PubMed ID: 17390761
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
Halliday A; Bates PA; Chance ML; Taylor MJ
Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
Bemani E; Oryan A; Bahrami S
Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases.
Al-Abdely HM; Graybill JR; Loebenberg D; Melby PC
Antimicrob Agents Chemother; 1999 Dec; 43(12):2910-4. PubMed ID: 10582881
[TBL] [Abstract][Full Text] [Related]
10. Treatment with synthetic lipophilic tyrosyl ester controls Leishmania major infection by reducing parasite load in BALB/c mice.
Sghaier RM; Aissa I; Attia H; Bali A; Leon Martinez PA; Mkannez G; Guerfali FZ; Gargouri Y; Laouini D
Parasitology; 2016 Oct; 143(12):1615-21. PubMed ID: 27312247
[TBL] [Abstract][Full Text] [Related]
11. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
Nabors GS; Farrell JP
Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
[TBL] [Abstract][Full Text] [Related]
12. Leishmania tropica: suggestive evidences for the effect of infectious dose on pathogenicity and immunogenicity in an experimental model.
Rostamian M; Jafari D; Abolghazi M; Farahani H; Niknam HM
Parasitol Res; 2018 Sep; 117(9):2949-2956. PubMed ID: 29978420
[TBL] [Abstract][Full Text] [Related]
13. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
Courret N; Lang T; Milon G; Antoine JC
Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
[TBL] [Abstract][Full Text] [Related]
14. Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions.
Peniche AG; Renslo AR; Melby PC; Travi BL
Antimicrob Agents Chemother; 2015 Oct; 59(10):6463-70. PubMed ID: 26239994
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of wheal-and-flare suppression among various non-sedating antihistamines and the pharmacologic insights to their efficacy.
Roongapinun S; Wajajamreon S; Fooanant S
J Med Assoc Thai; 2004 May; 87(5):551-6. PubMed ID: 15222528
[TBL] [Abstract][Full Text] [Related]
16. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice.
Uzonna JE; Bretscher PA
Eur J Immunol; 2001 Nov; 31(11):3175-84. PubMed ID: 11745334
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.
Khadem F; Jia P; Mou Z; Feiz Barazandeh A; Liu D; Keynan Y; Uzonna JE
J Antimicrob Chemother; 2017 Feb; 72(2):467-477. PubMed ID: 27999013
[TBL] [Abstract][Full Text] [Related]
20. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
